within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX18_Avapritinib;
model Avapritinib 
   extends Pharmacolibrary.Drugs.ATC.L.L01EX18;

  annotation(Documentation(
    info ="<html><body><p>Avapritinib is a tyrosine kinase inhibitor that selectively inhibits KIT and PDGFRA mutant kinases. It is primarily used for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST) harboring a PDGFRA exon 18 mutation, including D842V mutations. Avapritinib was approved by the US FDA in 2020 for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with unresectable or metastatic GIST after oral administration of avapritinib under fasting conditions.</p><h4>References</h4><ol><li><p>Yue, Z, et al., &amp; Sheng, Y (2024). Evaluation of Bioequivalence for Avapritinib Tablets in Chinese Participants Under Fasting Conditions Using a Reference-Scaled Average Bioequivalence Method. <i>Clinical pharmacology in drug development</i> 13(6) 672–676. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1398&quot;>10.1002/cpdd.1398</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38523571/&quot;>https://pubmed.ncbi.nlm.nih.gov/38523571</a></p></li><li><p>Wang, HJ, et al., &amp; Qiu, XJ (2021). The Pharmacokinetic Effect of Itraconazole and Voriconazole on Ripretinib in Beagle Dogs by UPLC-MS/MS Technique. <i>Drug design, development and therapy</i> 15 4865–4873. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S337864&quot;>10.2147/DDDT.S337864</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34876808/&quot;>https://pubmed.ncbi.nlm.nih.gov/34876808</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Avapritinib;
